© 2021 Marker Therapeutics, Inc.
…Phase I Trial analyses shows safety and positive immune response data
SEATTLE, June 23, 2015 /PRNewswire/ – TapImmune Inc. (TPIV) is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial. In this Phase 1 trial conducted at the Mayo Clinic in Rochester, MN, women diagnosed with HER2+ breast cancer (Stages II-III) that had completed standard treatment (i.e.
…SEATTLE, June 2, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), a clinical stage cancer immunotherapy company, and its institutional investors have reached an agreement whereby the institutional investors will have the option to exercise their short term warrants to provide the Company up to $4.93M in near term funding, pending closing conditions and an effective S-1 registration statement.